Founded in 1981, China National Pharmaceutical Foreign Trade Corporation (Sinopharm Foreign Trade) is a wholly-owned subsidiary of China Sinopharm International Corporation (Sinopharm International) and a member company of China National Pharmaceutical Group Corporation (Sinopharm), China's only centrally state-owned enterprise in the health sector directly managed by the State-owned Assets Supervision and Administration Commission of the State Council. Founded under the direct administration of State Pharmaceutical Administration Committee (SPAC, later NMPA), with the previous name of China Pharmaceutical Corporation for International Economic and Technological Cooperation, Sinopharm Foreign Trade is one of the first Chinese companies to enter into international businesses in the medicine and health sector. In 1998, Sinopharm Foreign Trade joined hands with three other companies affiliated to the State Pharmaceutical Administration Committee to form Sinopharm. Then in 2010, it merged with two other state-owned enterprises into Sinopharm International, a subsidiary of Sinopharm.
As an early starter in China's cooperation with foreign peers in the field of medicine, Sinopharm Foreign Trade, on behalf of China, has set up about a dozen Sino-foreign pharmaceutical joint ventures, including China Otsuka Pharma, Sino-Swed Pharma, and Xian Janssen Pharma, and has made quite successful international investments in relevant industries. For example, Vietnam-China Pharmaceutical Joint Stock Company (VCP) was established in Vietnam with investment from Sinopharm Foreign Trade in 2003, which is a modern manufacturer of injectable powder in Vietnam that is certified to the Good Manufacturing Practice (GMP) of the World Health Organization (WHO).
Having been engaged in international trade and related value-added services in the medicine, medical care and health sector for more than four decades, Sinopharm Foreign Trade has accumulated diversified and abundant resources which reinforce the formation of multi-category supply chains and international trade channels in the fields of medical devices, pharmaceuticals, life science, healthcare, pharmaceutical chemicals, etc.. It has so far obtained or helped its suppliers obtain overseas licenses for several hundred APIs, pharmaceutical preparations, and biological products. Meanwhile, it also boasts long-lasting and strong ties with many world-leading suppliers as well as international organizations such as the World Health Organization and the Pan American Health Organization based on mutual trust.
Serving both domestic and overseas corporate clients, Sinopharm Foreign Trade is able to provide integrated import and export supply chain management services by utilizing its modernized bonded pharmaceutical logistics center and warehousing logistics center for medical devices, giving the company remarkable resources and advantages in the distribution service of pharmaceuticals. For medical institutions, Sinopharm Foreign Trade leverages its strengths in pooling resources of medical and healthcare products and services to offer efficient, advanced, customized and complete solutions for the relevant medical departments, and versatile services such as medical device centralized procurement and delivery services, technical services and others.
Sinopharm Foreign Trade is licensed for an extensive range of businesses within the industry, such as medical devices, pharmaceuticals, food, hazardous chemicals, and third-party logistics. It is also a pharmaceutical company in Beijing to obtain GSP certification at an early stage and has secured the advanced AEO certificate (the highest level of credit certification granted by Customs authorities) to ensure facilitation for customs clearance within China as well as in countries that have AEO mutual recognition arrangements with China. Furthermore, Sinopharm Foreign Trade has an AAA credit rating and is a national model institution of business integrity in China. It is also a Grade-1 enterprise for export tax refund, and boasts a sound rating among the customs, commerce, industry and commerce, taxation, foreign exchange and other authorities as well as multiple financial institutions at home and abroad.
In the future, Sinopharm Foreign Trade will continue upholding the corporate philosophy of "All for Health, Health for All" and carrying forward the spirit of "Aspire and Achieve". It will go all out to fulfill its responsibilities as a centrally state-owned enterprise and become a supporting platform for the medicine and health industry with global influence, thus contributing to the development of the medicine and health sector in China and the world.